Reiseimpfungen – Hinweise und Empfehlungen

Key words

travel medicine - travel vaccines - immunocompromised travelers - paediatric travelers - pregnant travelers

Publication History

Article published online:
08 April 2024

• Literatur

• 1 Ständige Impfkommission und Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. unter besonderer Mitarbeit von Kling K, Külper-Schiek W, Rothe C, et al Empfehlungen der Ständigen Impfkommission (STIKO) und der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. (DTG) zu Reiseimpfungen. Epid Bull 2023; 14: 1-193 DOI: 10.25646/11201.4.
• 2 Steffen R, Behrens RH, Hill DR. et al Vaccine-preventable travel health risks: what is the evidence – what are the gaps?. J Travel Med 2015; 22: 1-12 DOI: 10.1111/jtm.12171.
• 3 Connor BA, Dawood R, Riddle MS. et al Cholera in travellers: a systematic review. J Travel Med 2019; 26: pii: taz085 DOI: 10.1093/jtm/taz085.
• 4 World Health Organization. Poliovirus IHR Emergency Committee 2024. Im Internet https://www.who.int/groups/poliovirus-ihr-emergency-committee
• 5 World Health Organization. International Travel and Health – 18 November 2022, Revised on 3 January 2023 Country List – Country vaccination requirements and WHO recommendations for vaccination against yellow fever, poliomyelitis, and malaria prophylaxis in international travellers. 2022 ed. Geneva: WHO. 2022: 46
• 6 The Embassy of the Kingdom of Saudi Arabia. Hajj and Umrah Health Requirements. Im Internet https://www.saudiembassy.net/hajj-and-umrah-health-requirements
• 7 Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit. Weltwärts-Untersuchungen. Im Internet https://www.dtg.org/index.php/liste-tropenmedizinischer-institutionen/weltwaerts-informationen-fueraerzte.html
• 8 Ständige Impfkommission: Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2024 Epid Bull. 2024; 04: 1-72 DOI: 10.25646/11892.2.
• 9 Piechotta V, Koch J, Berner R. et al Aktualisierung der COVID-19-Impfempfehlung in den allgemeinen Empfehlungen der STIKO 2024 und die dazugehörige wissenschaftliche Begründung. Epid Bull 2024; 02: 3-19 DOI: 10.25646/1189410.
• 10 Harris A.. Hepatitis B. In: CDC (Ed.). Yellow Book 2024. Oxford University Press: Section 5. Im Internet. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-b
• 11 Heyward WL, Kyle M, Blumenau J. et al Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine 2013; 31: 5300-5305 DOI: 10.1016/j.vaccine.2013.05.068.
• 12 Vesikari T, Langley JM, Segall N. et al Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021; 21: 1271-1281 DOI: 10.1016/S1473-3099(20)30780-5.
• 13 Steffen R, Chen LH, Leggat PA. Travel vaccines-priorities determined by incidence and impact. J Travel Med 2023; 30: taad085 DOI: 10.1093/jtm/taad085.
• 14 Hirve S, Newman LP, Paget J. et al Influenza Seasonality in the Tropics and Subtropics – When to Vaccinate?. PLoS One 2016; 11: e0153003 DOI: 10.1371/journal.pone.0153003.
• 15 Laws JH, Baumann U, Bogdan C. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 588-644 DOI: 10.1007/s00103-020-03123-w.
• 16 Bundeszentrale für gesundheitliche Aufklärung. Masernschutz.de. Im Internet https://www.masernschutz.de
• 17 Gershman M, Staples JE.. Yellow Fever. In: CDC (Ed.). Yellow Book 2024. Oxford University Press: Section 5. Im Internet https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/yellow-fever
• 18 Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol 2015; 64: 160-173 DOI: 10.1016/j.jcv.2014.08.030.
• 19 NaTHNaC. Yellow fever vaccine recommendation maps. Im Internet https://nathnacyfzone.org.uk/factsheet/60/yellow-fever-vaccine-recommendation-maps
• 20 Kling K, Bogdan C, Burchard G. et al STIKO-Empfehlung zur Gelbfieber-Auffrischimpfung vor Reisen in Endemiegebiete und für exponiertes Laborpersonal. Epid Bull 2022; 32: 3-35 DOI: 10.25646/10363.
• 21 Kling K, Domingo C, Bogdan C. et al Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis. Clin Infect Dis 2022; 75: 2266-2274 DOI: 10.1093/cid/ciac580.
• 22 Schnyder JL, de Jong HK, Bache BE. et al Long-term immunity following yellow fever vaccination: a systematic review and meta-analysis. Lancet Glob Health 2024; 12: e445-e456 DOI: 10.1016/S2214-109X(23)00556-9.
• 23 Gnanadurai R, Campo-Matos I, Kanagarajah S. et al National review of reported Yellow fever vaccine incidents in the UK. Travel Med Infect Dis 2022: 102289 DOI: 10.1016/j.tmaid.2022.102289
• 24 Staples JE, Monath TP, Gershman MD, Barrett ADT. Yellow Fever Vaccines. In: Orenstein W, Offit P, Edwards KM, Plotkin S (Eds.). Plotkin’s Vaccines. 7th ed. Philadelphia: Elsevier 2017: 1181-1265
• 25 StAR. Aufklärungsmerkblatt, Fragebogen und Einverständniserklärung vor Impfung gegen Gelbfieber. Im Internet https://www.dtg.org/images/Startseite-Download-Box/Gelbfieber-Aufklaerung_DTG_STAR_0223.pdf
• 26 Bwaka A, Bita A, Lingani C. et al Status of the rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018. J Infect Dis 2019; 220 (Suppl. 04) S140-S147 DOI: 10.1093/infdis/jiz336.
• 27 Peterson ME, Li Y, Bita A. et al Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health 2019; 09: 010409 DOI: 10.7189/jogh.09.010409.
• 28 Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis 2012; 25: 507-517 DOI: 10.1097/QCO.0b013e3283574c06.
• 29 Memish ZA, Goubeaud A, Bröker M. et al Invasive meningococcal disease and travel. J Infect Public Health 2010; 03: 143-151 DOI: 10.1016/j.jiph.2010.09.008.
• 30 Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med 2010; 17 Suppl 9-17 DOI: 10.1111/j.1708-8305.2010.00449.x.
• 31 Ruiz Garcia Y, Abitbol V, Pellegrini M. et al A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. Infect Dis Ther 2022; 11: 639-655 DOI: 10.1007/s40121-021-00519-2.
• 32 Haidara FC, Umesi A, Sow SO. et al Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia. N Engl J Med 2023; 388: 1942-1955 DOI: 10.1056/NEJMoa2214924.
• 33 Peterson J, Drazan D, Czajka H. et al Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Lancet Infect Dis 2023; 23: 1370-1382 DOI: 10.1016/S1473-3099(23)00191-3.
• 34 Steffen R, Caumes E. Three novel pentavalent meningococcal vaccines. J Travel Med 2024; 31: taad152 DOI: 10.1093/jtm/taad152.
• 35 World Health Organization. Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024. Weekly Epidemiological Record; 12 January 2024
• 36 Ministry of Health, Kingdom of Saudi Arabia. Health Requirements and Recommendations for Travelers to Saudi Arabia for Hajj – 1445H (2024). Im Internet https://www.moh.gov.sa/en/HealthAwareness/Pilgrims_Health/Documents/Health-Regulations-En.pdf
• 37 World Health Organization. Vaccination schedule for Meningococcal disease. Im Internet https://immunizationdata.who.int/pages/schedule-by-disease/meningococcal.html
• 38 Piechotta V, Koch J, Bogdan C. et al Empfehlung zur Standardimpfung von Säuglingen gegen Meningokokken der Serogruppe B und die dazugehörige wissenschaftliche Begründung. Epid Bull 2024; 03: 3-32 DOI: 10.25646/11900.
• 39 World Health Organization. Statement following the Thirty-seventh Meeting of the IHR Emergency Committee for Polio. 11 December 2023. Im Internet https://www.who.int/news/item/22-12-2023-statement-following-the-thirty-seventh-meeting-of-the-ihr-emergency-committee-for-polio
• 40 World Health Organization. Global Circulating Vaccine-derived Poliovirus (cVDPV). 20.February 2024. Im Internet https://polioeradication.org/wp-content/uploads/2024/02/weekly-polio-analyses-cVDPV-20240220.pdf
• 41 Konopka-Anstadt JL, Campagnoli R, Vincent A. et al Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines 2020; 05: 26 DOI: 10.1038/s41541-020-0176-7.
• 42 Global Polio Eradication Initiative. GPEI press release on nOPV2 prequalification. 09/01/2024. Im Internet https://polioeradication.org/news-post/gpei-press-release-on-nopv2-prequalification/
• 43 Steffen R, Acar J, Walker E. et al Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med Infect Dis 2003; 01: 80-88 DOI: 10.1016/S1477-8939(03)00062-0.
• 44 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch für 2020. Berlin; 2021
• 45 Nürnberg M, Equihua Martinez G, Jacob D. et al Two cases of imported cholera in Germany after short business travel to Yaoundé, Cameroon. J Travel Med 2023; 30: taad098 DOI: 10.1093/jtm/taad098.
• 46 McCarty JM, Cassie D, Bedell L. et al Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States. Am J Trop Med Hyg 2021; 104: 1758-1760 DOI: 10.4269/ajtmh.20-1576.
• 47 McCarty J, Bedell L, De Lame PA. et al Update on CVD 103-HgR single-dose, live oral cholera vaccine. Expert Rev Vaccines 2022; 21: 9-23 DOI: 10.1080/14760584.2022.2003709.
• 48 Collins JP, Ryan ET, Wong KK. et al Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022. MMWR Recomm Rep 2022; 71: 1-8 DOI: 10.15585/mmwr.rr7102a1.
• 49 World Health Organization. Dengue and severe dengue. 17 March 2023. Im Internet https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
• 50 Deutsche Gesetzliche Unfallversicherung. BK 3102. Im Internet https://www.dguv.de/bk-info/icd-10-kapitel/kapitel_01/bk3102/index.jsp
• 51 Sanchez-Vegas C, Hamer DH, Chen LH. et al Prevalence of dengue virus infection in US travelers who have lived in or traveled to dengue-endemic countries. J Travel Med 2013; 20: 352-360 DOI: 10.1111/jtm.12057.
• 52 Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine 2017; 35: 6355-6358 DOI: 10.1016/j.vaccine.2017.09.089.
• 53 Tricou V, Yu D, Reynales H. et al Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health 2024; 12: e257-e270 DOI: 10.1016/S2214-109X(23)00522-3.
• 54 Tricou V, Low JG, Oh HM. et al Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine 2020; 38: 1513-1519 DOI: 10.1016/j.vaccine.2019.11.061.
• 55 Kling K, Külper-Schiek W, Schmidt-Chanasit J. et al STIKO-Empfehlung und wissenschaftliche Begründung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epid Bull 2023; 48: 3-43 DOI: 10.25646/11784.
• 56 Ständiger Ausschuss Reisemedizin der DTG. Zur Impfung gegen Denguefieber mit Qdenga®. 16.02.2024. Im Internet https://www.dtg.org/index.php/aktuelles/mitteilungen-der-dtg.html
• 57 Robert Koch-Institut. FSME: Risikogebiete in Deutschland (Stand: Januar 2023) Epid Bull. 2023; 09: 3-22 DOI: 10.25646/11176.
• 58 Van Heuverswyn J, Hallmaier-Wacker LK, Beauté J. et al Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012 to 2020. Euro Surveill 2023; 28: 2200543 DOI: 10.2807/1560-7917.ES.2023.28.11.2200543.
• 59 Robert Koch-Institut. FSME-Risikogebiete in Deutschland (Stand: Januar 2024) Epid Bull. 2024; 09: 3-21 DOI: 10.25646/11965.
• 60 European Centre for Disease Prevention and Control. Tickborne encephalitis. In: ECDC. Annual epidemiological report for 2020. Stockholm: ECDC; 2022. Im Internet https://www.ecdc.europa.eu/en/publications-data/tickborne-encephalitis-annual-epidemiological-report-2020
• 61 Hansson KE, Rosdahl A, Insulander M. et al Tick-borne Encephalitis Vaccine Failures: A 10-year Retrospective Study Supporting the Rationale for Adding an Extra Priming Dose in Individuals Starting at Age 50 Years. Clin Infect Dis 2020; 70: 245-251 DOI: 10.1093/cid/ciz176.
• 62 Erber W, Khan F, Zavadska D. et al Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine 2022; 40: 819-825 DOI: 10.1016/j.vaccine.2021.12.028.
• 63 Nygren TM, Pilic A, Böhmer MM. et al Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany. Sci Rep 2022; 12: 11706 DOI: 10.1038/s41598-022-15447-5.
• 64 Steffen R, Erber W, Schmitt HJ. Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? – A systematic review. Ticks Tick Borne Dis 2021; 12: 101779 DOI: 10.1016/j.ttbdis.2021.101779.
• 65 Schmidt SM. Impfen: Was tun bei bestehenden Allergien? Dtsch Arztebl. 2018: 115 Supplement: Perspektiven der Pneumologie & Allergologie DOI: 10.3238/PersPneumo.2018.03.09.01
• 66 Wiedermann-Schmidt U, Maurer W. [Adjuvants and additives in vaccines--medical relevance]. Wien Klin Wochenschr 2005; 117: 510-519 DOI: 10.1007/s00508-005-0405-0.
• 67 Balogun O, Brown A, Angelo DO KM. et al Acute hepatitis a in international Travelers: A GeoSentinel analysis, 2008–2020. J Travel Med 2022: taac013 DOI: 10.1093/jtm/taac013
• 68 Furuya-Kanamori L, Gyawali N, Mills DJ. et al The Emergence of Japanese Encephalitis in Australia and the Implications for a Vaccination Strategy. Trop Med Infect Dis 2022; 07: 85 DOI: 10.3390/tropicalmed7060085.
• 69 Srivastava KS, Jeswani V, Pal N. et al Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines. Vaccines (Basel) 2023; 11: 742 DOI: 10.3390/vaccines11040742.
• 70 Hills SL, Walter EB, Atmar RL. et al Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2019; 68: 1-33 DOI: 10.15585/mmwr.rr6802a1.
• 71 Kling K, Harder T, Younger Z. et al Vaccination against Japanese encephalitis with IC51 systematic review on immunogenicity, duration of protection and safety. J Travel Med 2020; 27: taaa016 DOI: 10.1093/jtm/taaa016.
• 72 AG Reiseimpfungen der Ständigen Impfkommission (STIKO) Kling K, Bogdan C, Burchard G. et al Wissenschaftliche Begründung für die Empfehlung zur Impfung gegen Japanische Enzephalitis bei Reisen in Endemiegebiete und für Laborpersonal. Epid Bull 2020; 18: 5-27 DOI: 10.25646/6669.
• 73 European Food Safety Authority (EFSA); European Centre for Disease Prevention and Control (ECDC) The European Union One Health 2022 Zoonoses Report. EFSA J 2023; 21: e8442 DOI: 10.2903/j.efsa.2023.8442.
• 74 Heitkamp C, Stelzl DR, Ramharter R. et al Rabies exposure in travellers to Asia, the Middle East, Africa, South and Central America – a German Airport study. J Travel Med 2020; 27: taaa058 DOI: 10.1093/jtm/taaa058.
• 75 Gautret P, Angelo KM, Asgeirsson H. et al Rabies post-exposure prophylaxis started during or after travel: A GeoSentinel analysis. PLoS Negl Trop Dis 2018; 12: e0006951 DOI: 10.1371/journal.pntd.0006951.
• 76 Henry RE, Blanton JD, Angelo KM. et al A country classification system to inform rabies prevention guidelines and regulations. J Travel Med 2022; 29: taac046 DOI: 10.1093/jtm/taac046.
• 77 World Health Organization Rabies Vaccines: WHO position paper – April 2018. Weekly epidemiological record 2018; 93: 201-220
• 78 Auswärtiges Amt. Vorgehen bei Kontakt mit tollwutverdächtigen Tieren im Ausland. 01/22. Im Internet https://www.auswaertiges-amt.de/blob/251026/63ede1f7da0361ace59b36be85951e9b/tollwutkontakt-data.pdf
• 79 GBD 2017 Typhoid and Paratyphoid Collaborators The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19: 369-381 DOI: 10.1016/S1473-3099(18)30685-6.
• 80 Hancuh M, Walldorf J, Minta AA. et al Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction – Worldwide, 2018–2022. MMWR Morb Mortal Wkly Rep 2023; 72: 171-176 DOI: 10.15585/mmwr.mm7207a2.
• 81 Falkenhorst G, Enkelmann J, Faber M. et al Zur Situation bei wichtigen Infektionskrankheiten – Importierte Infektionskrankheiten 2022. Epid Bull 2023; 46: 3-20 DOI: 10.25646/11768.2.
• 82 Yousafzai MT, Qamnar FN, Shakoor S. et al Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine. Clin Infect Dis 2019; 68 (Suppl. 01) S16-S21 DOI: 10.1093/cid/ciy877.
• 83 Posen HJ, Wong W, Farrar DS. et al Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. J Travel Med 2023; 30: taac086 DOI: 10.1093/jtm/taac086.
• 84 Carey ME, McCann NS, Gibani MM. Typhoid fever control in the 21st century: where are we now?. Curr Opin Infect Dis 2022; 35: 424-430 DOI: 10.1097/QCO.0000000000000879.
• 85 Meiring JE, Shakya M, Khanam F. et al Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Glob Health 2021; 09: e1688-e1696 DOI: 10.1016/S2214-109X(21)00370-3.
• 86 Faucher JF, Binder R, Missinou MA. et al Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147-1154 DOI: 10.1086/342908.
• 87 UK Health Security Agency. Typhoid: the green book, chapter 33. 3 April 2020. Im Internet https://www.gov.uk/government/publications/typhoid-the-green-book-chapter-33
• 88 Patel PD, Liang Y, Meiring JE. et al Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet 2024; 403: 459-468 DOI: 10.1016/S0140-6736(23)02031-7.
• 89 Robert Koch-Institut. RSV-Infektionen. 02.02.2024. Im Internet https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html
• 90 Ehl S, Bogdan C, Niehues T. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1034-1051 DOI: 10.1007/s00103-018-2761-8.
• 91 Niehues T, Bogdan C, Hecht J. et al Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 674-684 DOI: 10.1007/s00103-017-2555-4.
• 92 Wagner N, Assmus F, Arendt G. et al Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 494-515 DOI: 10.1007/s00103-019-02905-1.
• 93 Chang L, Lim BCW, Flaherty GT. et al Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med 2019; 26: taz034 DOI: 10.1093/jtm/taz034.
• 94 Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice. Rheumatology (Oxford) 2021; 60: 3969-3976 DOI: 10.1093/rheumatology/keab445.
• 95 Robert Koch-Institut. Schutzimpfung gegen Gelbfieber: Häufig gestellte Fragen und Antworten. 16.1.2023. Im Internet https://www.rki.de/SharedDocs/FAQ/Impfen/Gelbfieber/FAQ-Liste_Gelbfieber_Impfen.html
• 96 Rosdahl A, Herzog C, Frösner G. et al An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study. Travel Med Infect Dis 2018; 21: 43-50 DOI: 10.1016/j.tmaid.2017.12.004.
• 97 Eperon G, Bühler S, Enriquez N. et al [The immunosuppressed traveler: vaccination guidelines]. Rev Med Suisse 2018; 14: 922-933
• 98 Huber F, Ehrensperger B, Hatz C. et al Safety of live vaccines on immunosuppressive or immunomodulatory therapy – a retrospective study in three Swiss Travel Clinics. J Travel Med 2018: 25 DOI: 10.1093/jtm/tax082
• 99 Bühler S, Jaeger VK, Eperon G. et al Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy – a prospective multi-centre pilot study1. J Travel Med 2020; 27: taaa126 DOI: 10.1093/jtm/taaa126.
• 100 Wechsler ME, Souza-Machado A, Xu C. et al Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines. J Allergy Clin Immunol Glob 2021; 01: 9-15 DOI: 10.1016/j.jacig.2021.12.003.
• 101 Emi Aikawa N, Andrade Balbi V, Borba EF. et al Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine X 2021; 10: 100131 DOI: 10.1016/j.jvacx.2021.100131.